[Translation] A multicenter, open-label, Phase I/II clinical study of the safety, tolerability, pharmacokinetics, and efficacy of FH-006 for injection in patients with malignant solid tumors
评估FH-006在晚期恶性实体瘤受试者中的安全性和耐受性,并确定最大耐受剂量(MTD)或最大给药剂量(MAD)和II期临床研究推荐剂量(RP2D)。
[Translation] To evaluate the safety and tolerability of FH-006 in subjects with advanced malignant solid tumors and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended dose (RP2D) for Phase II clinical studies.